Ajai Chari, MD, obtained his medical degree from the University of California, Los Angeles, CA, followed by his residency in internal medicine at Columbia University, New York, NY. This was followed by a fellowship in hematology and oncology at the University of California.
Prof. Chari is currently Professor of Medicine and Director of Clinical Research in the multiple myeloma program, and the Associate Director of Clinical Research at Mount Sinai. He has won several awards for his contribution to teaching and oncology, including the Ewig Teaching Award, Department of Medicine, Columbia University College of Physicians and Surgeons, and also the Health Care Provider of the year from the Leukemia Lymphoma Society.
Speaking on the development of novel chemotherapy regimens
Prof. Chari’s research includes the development of novel chemotherapy regimens, particularly Phase I and II studies. He has a clinical an interest in plasma cell disorders, such as multiple myeloma, AL amyloidosis, POEMS syndromes, plasmacytoma, and monoclonal gammopathies, where he has published substantially on these topics and has given talks regionally, nationally, and also internationally.
As Director of Clinical Research in the multiple myeloma program, Prof. Chari has supervised a program acclaimed nationally for its high quality assurance, which has played a pivotal role in the approval of each of the five most recent drugs to be approved by the FDA for the treatment of multiple myeloma.